Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience Coronavirus in patients with thalassemias

Main Article Content

Mehran Karimi
Sezaneh Haghpanah
Azita Azarkeivan
Sara Matin
Arash Safaei
Vincenzo De Sanctis





Download data is not yet available.

Abstract 925
PDF Downloads 282
HTML Downloads 113


1. European Centre for Disease Prevention and Control. COVID-19 situation update
worldwide, as of 7 September 2020.
2. Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q, Cao F, Jiang T, Sun J, Xu G, Chang C. Managementand treatment of COVID-19: the Chinese experience. Can J Cardiol. 2020; 36:915-930. .
3. de Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C, Soliman AT, Wali Y, Alkindi S, Huseynov V, Nasibova A, Tiryaki TO, Evim MS, Gunes AM, Karakas Z, Christou S, Campisi S, Zarei T, Khater D, Oymak Y, Kaleva V, Stoyanova D, Banchev A, Galati MC, Yassin MA, Kakar S, Skafida M, Kilinc Y, Alyaarubi S, Verdiyevas N, Stoeva I, Raiola G, Mariannis D, Ruggiero L, Di Maio S. Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. Mediterr J Hematol Infect Dis. 2020;12(1): e2020046. Published 2020 Jul 1. doi:10.4084/MJHID.2020.046.
4. Karimi M, De Sanctis V. Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the "high clinical risk" category? Acta Biomed. 2020; 91:50–56.
5. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP. COVID-19 in persons with haematological cancers. Leukemia. 2020; 34:1637-1645.
6. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; NEJMoa2020283. doi:10.1056 /NEJMoa2020283.
7. Modell B. Global epidemiology of haemoglobin disorders and derived service indicators. Bull. World Health Organ.2008;86:480–487.
8. Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A.Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014;31:583-596.
9. World Health Organisation; 2020. National Health Commission of the People's Republic of China. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7) Available at: 202002 / 3b09b894ac9b4204a79db5b8912d4440.shtml2020. Accessed February 5, 2020.
10. CDC (Centers for Disease Control and Prevention): 2019-ncov/covid-data/investigations-discovery/assessing-risk-factor
11. Karimi M, Haghpanah S, Azarkeivan A, Zahedi Z, Zarei T, Akhavan Tavakoli M, Bazrafshan A, Shirkavand A, De Sanctis V. Prevalence and mortality in b-thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience. Br J Haematol. 2020;190:e137-e140.
12. Hooman Tadbiri, Maziar Moradi-Lakeh, Mohsen Naghavi. Letter to the editor: COVID-19 and all-cause excess mortality in Iran in spring 2020. Med J Islam Repub Iran. 2020 (22 Sep);34.125.

13. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6): e20200702. doi:10.1542/peds.2020-0702.
14. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol.2020;16:341-342.